5-Star Stocks Poised to Pop: Hologic

Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Hologic (NASDAQ:HOLX), a maker of products geared toward women's health care, has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Hologic's business, and see what CAPS investors are saying about the stock right now.

Hologic facts

Sources: Capital IQ (a division of Standard & Poor's), and Motley Fool CAPS.

Over on CAPS, 714 of the 733 members who have rated Hologic -- or 97% -- believe the stock will outperform the S&P 500 going forward. These bulls include Bamafan68 and TSIF.

Two weeks ago, Bamafan68 wrote that Hologic "has a very healthy market share for women's care products, including ThinPrep pap smears and Novasure endometrial ablation devices which treats abnormal bleeding on an outpatient basis." Our CAPS member continues: "With a HPV diagnostic test awaiting FDA approval and new HPV testing recommendations, I expect this company to grow."

In a pitch from last week, TSIF gladly updates our community on those developments:

Good pop from FDA approval of Cervista and the DNA test that have a good comprehensive outlook. Normally I stay way away from pharma/drug type companies, but Hologic already has a decent pipeline of products, good cash flow, good forward P/E, and good cash on hand. Looks like a good place to diversify.

What do you think about Hologic, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.